Repare Therapeutics Inc.: M&A transaction — Repare Therapeutics acquired by XenoTherapeutics for ~$2.20/sh plus CVR

Repare Therapeutics Inc.

Completion of acquisition by XenoTherapeutics; shareholders received ~$2.20 per share in cash plus one CVR per share.
Transaction approved by shareholders on Jan 16, 2026; court order obtained Jan 23, 2026.
Common shares to cease trading on Nasdaq on/about Jan 28, 2026; Form 15 to be filed to suspend reporting obligations.
All directors resigned; Jon Adkins (sole director of Purchaser) becomes sole director and officer of surviving corporation.
Contingent value rights (CVR) represent right to receive pro rata portion of potential future cash payments.

item 2.01 item 3.01 item 3.03 item 5.01 item 5.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Repare Therapeutics Inc. underwent a change of control involving XenoTherapeutics, Inc. and Xeno Acquisition Corp. for approximately US$2.20 per Common Share (closed 2026-01-28).

Action: change of control
Counterparty: XenoTherapeutics, Inc. and Xeno Acquisition Corp.
Consideration: approximately US$2.20 per Common Share
Closing: 2026-01-28

Exact text from the filing

by reference herein. Subject to the terms and conditions set forth in the Agreement, on January 28, 2026, the Shareholders received a cash payment of approximately US$2.20 per Common that was determined based upon the Company’s cash balance immediately prior to the closing of the Transaction (the “Closing”) after deducting certain transaction costs,

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001193125-26-027394

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.